SCHEMBL26023377

SCHEMBL26023377

COC(=O)CCc1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 14/20 0.79
▸ PDGFRB P09619 14/20 0.79
▸ FGFR1 P11362 13/20 0.79
▸ RET P07949 3/20 0.79
▸ FLT3 P36888 3/20 0.79
▸ AURKA O14965 2/20 0.79
▸ FLT1 P17948 2/20 0.79
▸ MAP4K2 Q12851 2/20 0.79
▸ STK3 Q13188 2/20 0.79
▸ AURKB Q96GD4 2/20 0.79
▸ CHEK1 O14757 2/20 0.79
▸ ALK Q9UM73 2/20 0.79
▸ GAK O14976 1/20 0.79
▸ RPS6KA5 O75582 1/20 0.79
▸ RPS6KA4 O75676 1/20 0.79
▸ LATS1 O95835 1/20 0.79
▸ CSNK2A2 P19784 1/20 0.79
▸ MAP2K2 P36507 1/20 0.79
▸ ZAP70 P43403 1/20 0.79
▸ MAP2K1 Q02750 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Orantinib SCHEMBL134661 0.88 FGFR1 (1.00) KDRPDGFRBFGFR1RETFLT3
Orantinib SCHEMBL900355 0.88 FGFR1 (1.00) KDRPDGFRBFGFR1RETFLT3
Orantinib SCHEMBL134662 0.88 FGFR1 (1.00) KDRPDGFRBFGFR1RETFLT3
Orantinib SCHEMBL29354645 0.88 FGFR1 (1.00) KDRPDGFRBFGFR1RETFLT3
SCHEMBL12020869 0.88 KDR (0.84) KDRPDGFRBFGFR1RETFLT3
SCHEMBL6861551 0.86 CHEK1 (0.71) KDRPDGFRBFGFR1RETFLT3
SCHEMBL6861547 0.86 CHEK1 (0.71) KDRPDGFRBFGFR1RETFLT3
SCHEMBL13497857 0.85 KDR (0.79) KDRPDGFRBFGFR1RETFLT3
SCHEMBL25717271 0.85 KDR (0.82) KDRPDGFRBFGFR1RETFLT3
SCHEMBL16366587 0.83 KDR (0.76) KDRPDGFRBFGFR1RETFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230263907-A1 PREPARATION OF SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERY Oculis Operations Sàrl (CH) 2023-08-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230263907-A1 PREPARATION OF SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERY ERBB3, EGFR, ERBB2 KDR 5/4885PDGFRB 86/4885FGFR1 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback